REYON Pharmaceutical Co., Ltd. (KRX:102460)
10,040
-50 (-0.50%)
Sep 11, 2026, 3:30 PM KST
REYON Pharmaceutical Revenue
REYON Pharmaceutical had revenue of 35.85B KRW in the quarter ending June 30, 2026, a decrease of -4.90%. This brings the company's revenue in the last twelve months to 143.37B, down -4.45% year-over-year. In the year 2025, REYON Pharmaceutical had annual revenue of 145.93B, down -1.60%.
Revenue (ttm)
143.37B
Revenue Growth
-4.45%
P/S Ratio
1.28
Revenue / Employee
311.01M
Employees
440
Market Cap
184.14B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 145.93B | -2.37B | -1.60% |
| Dec 31, 2024 | 148.30B | -2.77B | -1.83% |
| Dec 31, 2023 | 151.07B | -2.97B | -1.93% |
| Dec 31, 2022 | 154.04B | 11.24B | 7.87% |
| Dec 31, 2021 | 142.80B | 12.77B | 9.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chong Kun Dang Holdings | 961.64B |
| Daewon Pharmaceutical | 614.64B |
| Whan In Pharm | 273.47B |
| JW Lifescience | 253.71B |
| HLB Pharmaceutical | 251.95B |
| Daihan Pharmaceutical | 216.55B |
| Yungjin Pharm. | 158.79B |
| BNC KOREA | 91.19B |